Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 28Thoracic 9Breast 6Genitourinary 5Head & Neck 4Gastrointestinal 4Gynecologic 3Sarcoma 2Other solid neoplasm 2Lymphoid 1Endocrine 1

Conditions

Advanced Solid Tumor 6Solid Tumors 3Solid Tumor 3Mesothelioma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor, Adult 2Melanoma 2Cholangiocarcinoma 2Advanced Solid Tumors 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Esophageal Neoplasms 1DMMR Colorectal Cancer 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 12Nivolumab 6atezolizumab 3Ipilimumab 3tislelizumab 2spartalizumab 2durvalumab 2avelumab 2Etoposide 2ruxolitinib 1poly ICLC 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1entinostat 1cemiplimab 1budigalimab 1bemcentinib 1Thrombopoietin 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Levoleucovorin 1Leucovorin 1LY2940680 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × spartalizumab × Other solid neoplasm × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1/2 Completed
490 enrolled 77 charts
DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡